Localized HR-Positive Breast Cancer — Year in Review Series on Relevant New Datasets and Advances
About this episode
This episode reviews recent advancements and datasets in the treatment of localized HR-positive breast cancer with insights from leading experts.
Featuring perspectives from Dr Harold J Burstein and Dr Joyce O'Shaughnessy, including the following topics: Introduction: ODAC — April 30, 2026 (00:00) Adjuvant CDK4/6 Inhibitors (13:03) Adjuvant Oral Selective Estrogen Receptor Degraders (21:53) Premenopausal Patients (30:52) Duration of Adjuvant Endocrine Treatment (38:44) Genomic Predictors of Chemotherapy Benefit (47:19) Neoadjuvant Treatment (55:13) CME information and select publications
More episodes of Research To Practice | Oncology Videos
- EGFR-Mutated Non-Small Cell Lung Cancer — Proceedings from a Session Held in Conjunction with the 2026 ASCO Annual Meeting
- Endometrial Cancer — Proceedings from a Session Held in Conjunction with the 2026 ASCO Annual Meeting
- HER2-Positive Metastatic Breast Cancer — An Interview with Prof Dr Sibylle Loibl on First-Line and Maintenance Therapy
- HER2-Positive Metastatic Breast Cancer — An Interview with Prof Dr Sibylle Loibl on First-Line and Maintenance Therapy (Companion Faculty Lecture)
- For Oncology Nurses: Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia — Proceedings from the 2026 Annual ONS Congress
- Ovarian Cancer — Proceedings from a Session Held in Conjunction with the 2026 ASCO Annual Meeting
Explore listener stats, chart rankings, contacts and more on the Research To Practice | Oncology Videos podcast page.